Genetics of validated Parkinson’s disease subtypes in the Oxford Discovery and Tracking Parkinson’s cohorts

OBJECTIVES To explore the genetics of four Parkinson's disease (PD) subtypes that have been previously described in two large cohorts of patients with recently diagnosed PD. These subtypes came from a data-driven cluster analysis of phenotypic variables. METHODS We looked at the frequency of genetic mutations in glucocerebrosidase (GBA) and leucine-rich repeat kinase 2 against our subtypes. Then we calculated Genetic Risk Scores (GRS) for PD, multiple system atrophy, progressive supranuclear palsy, Lewy body dementia, and Alzheimer's disease. These GRSs were regressed against the probability of belonging to a subtype in the two independent cohorts and we calculated q-values as an adjustment for multiple testing across four subtypes. We also carried out a Genome-Wide Association Study (GWAS) of belonging to a subtype. RESULTS A severe disease subtype had the highest rates of patients carrying GBA mutations while the mild disease subtype had the lowest rates (p=0.009). Using the GRS, we found a severe disease subtype had a reduced genetic risk of PD (p=0.004 and q=0.015). In our GWAS no individual variants met genome wide significance (<5×10e-8) although four variants require further follow-up, meeting a threshold of <1×10e-6. CONCLUSIONS We have found that four previously defined PD subtypes have different genetic determinants which will help to inform future studies looking at underlying disease mechanisms and pathogenesis in these different subtypes of disease.

[1]  W. Heiser,et al.  The identification of Parkinson's disease subtypes using cluster analysis: A systematic review , 2010, Movement disorders : official journal of the Movement Disorder Society.

[2]  M. Nalls,et al.  Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson’s Disease , 2020, medRxiv.

[3]  R. Barker,et al.  Tracking Parkinson’s: Study Design and Baseline Patient Data , 2015, Journal of Parkinson's disease.

[4]  P. Visscher,et al.  10 Years of GWAS Discovery: Biology, Function, and Translation. , 2017, American journal of human genetics.

[5]  M. Ban,et al.  Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. , 2013, Brain : a journal of neurology.

[6]  G. Plazzi,et al.  Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies , 2021, Brain : a journal of neurology.

[7]  Y. Ben-Shlomo,et al.  Blood biomarkers with Parkinson's disease clusters and prognosis: The oxford discovery cohort , 2019, Movement disorders : official journal of the Movement Disorder Society.

[8]  K. Marder,et al.  Cognitive performance of GBA mutation carriers with early-onset PD , 2012, Neurology.

[9]  J. Jankovic,et al.  Juvenile parkinsonism: Differential diagnosis, genetics, and treatment. , 2019, Parkinsonism & related disorders.

[10]  Sonja W. Scholz,et al.  NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases , 2017, Neurobiology of Aging.

[11]  K. Dujardin,et al.  Parkinson’s Disease Subtypes: Critical Appraisal and Recommendations , 2021, Journal of Parkinson's disease.

[12]  P. Mazzoni,et al.  Parkinson disease phenotype in Ashkenazi jews with and without LRRK2 G2019S mutations , 2013, Movement disorders : official journal of the Movement Disorder Society.

[13]  T. Perneger What's wrong with Bonferroni adjustments , 1998, BMJ.

[14]  M. Okun,et al.  Parkinson's disease motor subtype changes during 20 years of follow-up. , 2020, Parkinsonism & related disorders.

[15]  R. Barker,et al.  Features of GBA-associated Parkinson’s disease at presentation in the UK Tracking Parkinson’s study , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[16]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[17]  Erdogan Taskesen,et al.  Functional mapping and annotation of genetic associations with FUMA , 2017, Nature Communications.

[18]  D. Hernandez,et al.  Genome-Wide Association Study Meta-Analysis for Parkinson Disease Motor Subtypes , 2021, Neurology: Genetics.

[19]  Ashley R. Jones,et al.  Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases , 2018, Molecular Neurodegeneration.

[20]  Y. Ben-Shlomo,et al.  Parkinson’s Disease Subtypes in the Oxford Parkinson Disease Centre (OPDC) Discovery Cohort , 2015, Journal of Parkinson's disease.

[21]  Tangchun Wu,et al.  Functional Variant in the SLC22A3-LPAL2-LPA Gene Cluster Contributes to the Severity of Coronary Artery Disease , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[22]  E. Tolosa,et al.  Motor and nonmotor heterogeneity of LRRK2‐related and idiopathic Parkinson's disease , 2016, Movement disorders : official journal of the Movement Disorder Society.

[23]  A. Schapira,et al.  Exploring the Genotype–Phenotype Correlation in GBA-Parkinson Disease: Clinical Aspects, Biomarkers, and Potential Modifiers , 2021, Frontiers in Neurology.

[24]  J. Jankovic,et al.  Young-onset Parkinson's disease: Its unique features and their impact on quality of life. , 2019, Parkinsonism & related disorders.

[25]  M. Albert,et al.  Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. , 2016, JAMA neurology.

[26]  Ze-Min Fang,et al.  Histone methyltransferase SMYD2: ubiquitous regulator of disease , 2019, Clinical Epigenetics.

[27]  N. Lazar,et al.  The ASA Statement on p-Values: Context, Process, and Purpose , 2016 .

[28]  Sonja W. Scholz,et al.  A genome-wide association study in multiple system atrophy , 2016, Neurology.

[29]  J. C. Cooke Bailey,et al.  Genetic Risk Scores , 2016, Current protocols in human genetics.

[30]  K. Marder,et al.  Progression in the LRRK2-Asssociated Parkinson Disease Population , 2018, JAMA neurology.

[31]  Ross M. Fraser,et al.  Genetic studies of body mass index yield new insights for obesity biology , 2015, Nature.

[32]  Sonja W. Scholz,et al.  Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies , 2019, The Lancet Neurology.

[33]  Genetics of 35 blood and urine biomarkers in the UK Biobank , 2020, Nature genetics.

[34]  Sina A. Gharib,et al.  Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression , 2021, Nature Genetics.

[35]  R. Barker,et al.  Genetic analysis of Mendelian mutations in a large UK population-based Parkinson’s disease study , 2019, Brain : a journal of neurology.

[36]  William J. Astle,et al.  The Polygenic and Monogenic Basis of Blood Traits and Diseases , 2020, Cell.

[37]  H. Sagar,et al.  A data‐driven approach to the study of heterogeneity in idiopathic Parkinson's disease: identification of three distinct subtypes , 1999, Movement disorders : official journal of the Movement Disorder Society.

[38]  J. Zarranz,et al.  Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene. , 2015, Parkinsonism & related disorders.

[39]  Jonathan A C Sterne,et al.  Sifting the evidence—what's wrong with significance tests? , 2001, BMJ : British Medical Journal.

[40]  Genetic,et al.  Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing , 2019, Nature Genetics.

[41]  J. Jankovic,et al.  Variable expression of Parkinson's disease , 1990, Neurology.

[42]  J. Hardy,et al.  Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course , 2012, Movement disorders : official journal of the Movement Disorder Society.

[43]  J. Jankovic,et al.  Parkinson disease subtypes. , 2014, JAMA neurology.

[44]  R. Barker,et al.  Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's , 2016, Annals of neurology.

[45]  J. Klein,et al.  Prodromal Parkinsonism and Neurodegenerative Risk Stratification in REM Sleep Behavior Disorder , 2017, Sleep.

[46]  Benjamin J. Wright,et al.  Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease , 2009, Nature Genetics.

[47]  R. Barker,et al.  Developing and validating Parkinson’s disease subtypes and their motor and cognitive progression , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[48]  Sonja W. Scholz,et al.  Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into the complex genetic architecture , 2020, bioRxiv.

[49]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[50]  E. Friedman,et al.  Motor progression of Parkinson's disease with the leucine‐rich repeat kinase 2 G2019S mutation , 2014, Movement disorders : official journal of the Movement Disorder Society.